alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
FILED

U.S. COURT OF APPEALS

ELEVENTH CIRCUIT

August 7, 2002

THOMAS K. KAHN

CLERK

[PUBLISH]

IN THE UNITED STATES COURT OF APPEALS

FOR THE ELEVENTH CIRCUIT

____________________

No. 01-13606

_____________________

D. C. Docket No. 99-00042-CV-WLS

WILLIE SANTONIO MANDERS, 

 Plaintiff-Appellee,

versus

THURMAN LEE, individually and as employee of the

City of Homerville, ALAN BROWN, individually and

as employee of the City of Homerville, BART CREWS,

individually and as employee of the City of 

Homerville, CITY OF HOMERVILLE, CLINCH COUNTY, GEORGIA, 

 Defendants,

WINSTON PETERSON, individually and as employee of

Clinch County, Georgia, 

 Defendant-Appellant.

___________________

Appeal from the United States District Court 

for the Middle District of Georgia

_____________________ 

(August 7, 2002)

(Opinion March 14, 2002, 285 F.3d 983) 

Before EDMONDSON, Chief Judge, and TJOFLAT, ANDERSON, BIRCH,

DUBINA, BLACK, CARNES, BARKETT, HULL, MARCUS and WILSON, Circuit

Judges.
2

BY THE COURT:

A member of this Court in active service having requested a poll on the

suggestion of rehearing en banc and a majority of the judges in this Court in active

service having voted in favor of granting a rehearing en banc,

IT IS ORDERED that the above cause shall be reheard by this court en banc.

The previous panel's opinion is hereby VACATED.
# C_2014431EN.01001001.xml

| 1.12.2014 | EN | Official Journal of the European Union | C 431/10 |
| --- | --- | --- | --- |

1.12.2014

EN

Official Journal of the European Union

C 431/10

---

Request for a preliminary ruling from the Nejvyšší soud České republiky (Czech Republic) lodged on 25 August 2014 — Marie Matoušková, court commissioner in inheritance proceedings v Misha Martinus and Elisabeth Jekaterina Martinus, represented by David Sedlák as trustee; Beno Jeriël Eljada Martinus

(Case C-404/14)

(2014/C 431/16)

Language of the case: Czech

Referring court

Referring court

Nejvyšší soud České republiky

Parties to the main proceedings

Parties to the main proceedings

Applicant: Marie Matoušková, court commissioner in inheritance proceedings

Applicant:

Persons concerned by the inheritance proceedings: Misha Martinus and Elisabeth Jekaterina Martinus, represented by David Sedlák as trustee; Beno Jeriël Eljada Martinus

Persons concerned by the inheritance proceedings:

Question referred

Question referred

If an inheritance settlement agreement concluded on behalf of a minor by his or her trustee requires the approval of a court in order to be valid, is that decision on the part of the court a measure within the meaning of Article 1(1)(b) or a measure within the meaning of Article 1(3)(f) of Council Regulation (EC) No 2201/2003 (1) of 27 November 2003 concerning jurisdiction and the recognition and enforcement of judgments in matrimonial matters and matters of parental responsibility, repealing Regulation (EC) No 1347/2000?

1

---

(1)  OJ 2003 L 338, p. 1.

1

---
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from 
Riverside Park Associates Limited Partnership 1998 First Quarter 10-QSB
and is qualified in its entirety by reference to such 10-QSB filing.
</LEGEND>
<CIK> 0000813812
<NAME> RIVERSIDE PARK ASSOCIATES LIMITED PARTNERSHIP
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                    3-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               MAR-31-1998   
<CASH>                                           2,463
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0<F1>
<PP&E>                                          73,345
<DEPRECIATION>                                  32,358   
<TOTAL-ASSETS>                                  45,412   
<CURRENT-LIABILITIES>                                0<F1>
<BONDS>                                         45,992     
<PREFERRED-MANDATORY>                                0     
<PREFERRED>                                          0  
<COMMON>                                             0
<OTHER-SE>                                     (1,753)    
<TOTAL-LIABILITY-AND-EQUITY>                    45,412    
<SALES>                                              0
<TOTAL-REVENUES>                                 2,647    
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                 2,984    
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               1,045    
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     (337)     
<EPS-PRIMARY>                                    (578)<F2>
<EPS-DILUTED>                                        0
<FN>
<F1>Registrant has an unclassified balance sheet.
<F2>Multiplier is 1.
</FN>
        


</TABLE>
# C_2014421EN.01002102.xml

| 24.11.2014 | EN | Official Journal of the European Union | C 421/21 |
| --- | --- | --- | --- |

24.11.2014

EN

Official Journal of the European Union

C 421/21

---

Request for a preliminary ruling from the Lietuvos Aukščiausiasis Teismas lodged on 18 September 2014 — Air Baltic Corporation AS v Lietuvos Respublikos specialiųjų tyrimų tarnyba

(Case C-429/14)

2014/C 421/31

Language of the case: Lithuanian

Referring court

Referring court

Lietuvos Aukščiausiasis Teismas

Parties to the main proceedings

Parties to the main proceedings

Appellant in cassation: Air Baltic Corporation AS

Appellant in cassation:

Other party to the proceedings: Lietuvos Respublikos specialiųjų tyrimų tarnyba

Other party to the proceedings:

Questions referred

Questions referred

| 1. | Are Articles 19, 22 and 29 of the Montreal Convention to be understood and interpreted as meaning that an air carrier is liable to third parties, inter alia to the passengers’ employer, a legal person with which a transaction for the international carriage of passengers was entered into, for damage occasioned by a flight’s delay, on account of which the applicant (the employer) incurred additional expenditure connected with the delay (for example, the payment of travel expenses)? |
| --- | --- |

1.

Are Articles 19, 22 and 29 of the Montreal Convention to be understood and interpreted as meaning that an air carrier is liable to third parties, inter alia to the passengers’ employer, a legal person with which a transaction for the international carriage of passengers was entered into, for damage occasioned by a flight’s delay, on account of which the applicant (the employer) incurred additional expenditure connected with the delay (for example, the payment of travel expenses)?

| 2. | If the first question is answered in the negative, is Article 29 of the Montreal Convention to be understood and interpreted as meaning that those third parties have the right to bring claims against the air carrier on other bases, for example, in reliance upon national law? |
| --- | --- |

2.

If the first question is answered in the negative, is Article 29 of the Montreal Convention to be understood and interpreted as meaning that those third parties have the right to bring claims against the air carrier on other bases, for example, in reliance upon national law?

---
§ 558.464 Poloxalene. ( a ) *Specifications.* Dry Type A medicated articles containing 53 percent poloxalene or liquid Type A medicated articles containing 99.5 percent poloxalene.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.517 of this chapter.
( d ) *Conditions of use.* ( 1 ) For prevention of legume (alfalfa, clover) and wheat pasture bloat in cattle.
( 2 ) Poloxalene dry Type A article and liquid Type A article must be thoroughly blended and evenly distributed in feed prior to use. This may be accomplished by adding the Type A article to a small quantity of feed, mixing thoroughly, then adding this mixture to the remaining feed and again mixing thoroughly. Dosage is 1 gram of poloxalene per 100 pounds of body weight daily and continued during exposure to bloat producing conditions. If bloating conditions are severe, the dose is doubled. Treatment should be started 2 to 3 days before exposure to bloat-producing conditions. Repeat dosage if animals are exposed to bloat-producing conditions more than 12 hours after the last treatment. Do not exceed the higher dosage levels in any 24-hour period.
[40 FR 39857, Aug. 29, 1975, as amended at 51 FR 7399, Mar. 3, 1986; 52 FR 2686, Jan. 26, 1987; 56 FR 50654, Oct. 8, 1991; 60 FR 55660, Nov. 2, 1995; 79 FR 13545, Mar. 11, 2014; 84 FR 33001, July 11, 2019]
§ 210.2 Applicability of current good manufacturing practice regulations. Cross Reference
Link to an amendment published at 89 FR 51769 , June 18, 2024.
( a ) The regulations in this part and in parts 211, 225, and 226 of this chapter as they may pertain to a drug; in parts 600 through 680 of this chapter as they may pertain to a biological product for human use; and in part 1271 of this chapter as they are applicable to a human cell, tissue, or cellular or tissue-based product (HCT/P) that is a drug (subject to review under an application submitted under section 505 of the act or under a biological product license application under section 351 of the Public Health Service Act); shall be considered to supplement, not supersede, each other, unless the regulations explicitly provide otherwise. In the event of a conflict between applicable regulations in this part and in other parts of this chapter, the regulation specifically applicable to the drug product in question shall supersede the more general.
( b ) If a person engages in only some operations subject to the regulations in this part, in parts 211, 225, and 226 of this chapter, in parts 600 through 680 of this chapter, and in part 1271 of this chapter, and not in others, that person need only comply with those regulations applicable to the operations in which he or she is engaged.
( c ) An investigational drug for use in a phase 1 study, as described in § 312.21(a) of this chapter, is subject to the statutory requirements set forth in 21 U.S.C. 351(a)(2)(B). The production of such drug is exempt from compliance with the regulations in part 211 of this chapter. However, this exemption does not apply to an investigational drug for use in a phase 1 study once the investigational drug has been made available for use by or for the sponsor in a phase 2 or phase 3 study, as described in § 312.21(b) and (c) of this chapter, or the drug has been lawfully marketed. If the investigational drug has been made available in a phase 2 or phase 3 study or the drug has been lawfully marketed, the drug for use in the phase 1 study must comply with part 211.
[69 FR 29828, May 25, 2004, as amended at 73 FR 40462, July 15, 2008; 74 FR 65431, Dec. 10, 2009]
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsRadiation Single Event Effects (SEE) Impact on Complex Avionics Architecture ReliabilityThe NASA Engineering and Safety Center (NESC) has an urgent need to understand how system-level reliability of an avionics architecture is compromised when portions of the architecture are temporarily unavailable due to single event effects (SEE). The proposed activity parametrically evaluated these SEE impacts on system reliability based on mission duration, upset rate and recovery times for a representative redundant architecture. The key stakeholders for this study are NASA programs and projects that expect to use avionics architectures with electrical, electronic and electromechanical (EEE) parts susceptible to SEE when exposed to the mission expected radiation environment.Document ID20190002742Acquisition SourceLangley Research CenterDocument TypeTechnical Memorandum (TM)AuthorsHodson, Robert F.*(NASA Langley Research Center Hampton, VA, United States)*Morgan, Dwayne*(NASA Wallops Flight Facility Wallops Island, VA, United States)*Ladbury, Raymond L.*(NASA Goddard Space Flight Center Greenbelt, MD, United States)*Chen, Yuan*(NASA Langley Research Center Hampton, VA, United States)*Bay, Michael*(Bay Engineering Innovations, Inc. Edgewater, MD, United States)*Zinchuk, Jeffrey*(Bay Engineering Innovations, Inc. Edgewater, MD, United States)*Date AcquiredApril 25, 2019Publication DateApril 1, 2019Subject CategorySpace Transportation And SafetyAvionics And Aircraft InstrumentationReport/Patent NumberNASA/TM-2019-220269NESC-RP-17-01211L-21015NF1676L-32877Funding Number(s)WBS: 869021.03.07.01.09Distribution LimitsPublicCopyrightPublic Use Permitted.Available DownloadsNameType20190002742.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsThere are no records associated with this record.visibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024
Exhibit 11 - Computation of Earnings Per Share

Earnings Per Share (EPS), presented below is the calculation of basic and
diluted EPS for the Company for the three months ended March 31, 2000 and 1999.

<TABLE>
<CAPTION>

                                                                              2000                1999*
                                                                       --------------------------------
<S>                                                                    <C>                  <C>
Income before minority interest                                        $ 5,052,438          $ 4,211,415
Less:    minority interest                                                   1,856                1,856
                                                                       -----------          -----------
Net income                                                             $ 5,050,582          $ 4,209,559

Weighted average shares outstanding                                     18,889,907           19,414,304
Plus: effect of stock options as dilutive securities                        71,168              181,378
                                                                       -----------          -----------
Adjusted weighted average shares assuming dilution                      18,961,075           19,595,682

EPS - Basic                                                            $      0.27          $       .21
EPS - Diluted                                                          $      0.27          $       .21


* Adjusted for the 2-1 stock split, effective October 1999.
-------------------------------------------------------------------------------------------------------
</TABLE>
### Late Holocene sedimentary environments of south San Francisco Bay, California, illustrated in gravity cores

By: Donald L. WoodrowTheresa A. FregosoFlorence L. Wong**Bruce E. Jaffe**

                            https://doi.org/10.3133/ofr20141198

#### Links

- More information:  **USGS Index Page**                            (html)
-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Metadata:  **Metadata**                            (html)
- Spatial Data:  **Spatial Data**                            (zip)
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

#### Study Area

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
Exhibit 31.2



CERTIFICATION



I, J. Timothy Gargaro, certify that:



1. I have reviewed this Quarterly Report on Form 10-Q of Exide Technologies;



2. Based on my knowledge, this report does not contain any
untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;



3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;



4. The registrants other certifying
officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) for the registrant and we have:



a. Designed such disclosure controls and procedures, or
caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;



b. Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end
of the period covered by this report based on such evaluation; and



c. Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the most recent fiscal quarter (the registrants fourth fiscal quarter in the case of
an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and



5. The registrants other certifying officer and I have disclosed, based on our most recent evaluation
of internal control of financial reporting, to the registrants auditors and the audit committee of registrants board of directors (or persons performing the equivalent function):



a. All significant deficiencies and material weaknesses in
the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and



b. Any fraud, whether or not material, that involves
management or other employees who have a significant role in the registrants internal control over financial reporting.



|    |  |                                                                        
|--- |  | -----------------------------------------------------------------------
|By: |  | /s/    J. TIMOTHY
GARGARO                                              
|    |  | J. Timothy Gargaro Executive Vice President and Chief Financial Officer



Date: November 15, 2004
§ 526.1696 Penicillin G procaine. ( a ) *Specifications.* Each single-dose, 10-milliliter syringe contains penicillin G procaine equivalent to 100,000 units of penicillin G.
( b ) See Nos. 042791 and 061133 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.510 of this chapter.
( d ) *Conditions of use in lactating cows* — ( 1 ) Amount . Infuse the contents of one 10-milliliter syringe (equivalent to 100,000 units penicillin G) into each infected quarter. Treatment may be repeated at 12-hour intervals for not more than 3 doses, as indicated by clinical response.
( 2 ) *Indications for use.* For the treatment of mastitis caused by *Streptococcus agalactiae, S. dysgalactiae,* and *S. uberus* in lactating cows.
( 3 ) *Limitations.* For intramammary infusion in lactating cows only. Discard all milk for 60 hours (5 milkings) after the latest treatment. Animals intended for human consumption must not be slaughtered within 3 days of latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( e ) *Conditions of use in dry cows* — ( 1 ) Amount . Infuse the contents of one 10-milliliter syringe (equivalent to 100,000 units penicillin G) into each infected quarter at time of drying-off.
( 2 ) *Indications for use.* For the treatment of mastitis caused by *Streptococcus agalactiae* in dry cows.
( 3 ) *Limitations.* For intramammary infusion in dry cows only. Animals intended for human consumption must not be slaughtered within 14 days of last treatment. Discard all milk for 72 hours (6 milkings) following calving, or later as indicated by the marketable quality of the milk. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[86 FR 13187, Mar. 8, 2021, as amended at 86 FR 57998, Oct. 20, 2021; 88 FR 27700, May 3, 2023; 88 FR 55567, Aug. 16, 2023]
EXHIBIT 32.1


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                   SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


      In connection  with the Quarterly  Report of Central  Wireless,  Inc. (the
"Company") on Form 10-QSB for the quarter ended March 31, 2005 as filed with the
Securities  and  Exchange  Commission  on the date  hereof (the  "Report"),  the
undersigned,  in the  capacities  and  on  the  dates  indicated  below,  hereby
certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that to his knowledge:

      1. The Report fully  complies  with the  requirements  of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

      2.  The  information  contained  in the  Report  fairly  presents,  in all
material  respects,  the  financial  condition  and results of  operation of the
Company.

Date  May 13, 2005                         By: /s/  Kenneth W. Brand
                                               ---------------------
                                           Name:  Kenneth W. Brand
                                           Title: Chief Executive Officer


      A signed  original of this written  statement  required by Section 906, or
other  document  authentications,   acknowledging,  or  otherwise  adopting  the
signature  that  appears in typed form  within  the  electronic  version of this
written  statement  required  by  Section  906,  has been  provided  to  Central
Wireless,  Inc. and will be retained by Central Wireless,  Inc. and furnished to
the Securities and Exchange Commission or its staff upon request.